Protagonist Therapeutics Ownership | Who Owns Protagonist Therapeutics?


OverviewForecastRevenueFinancialsChart

Protagonist Therapeutics Ownership Summary


Protagonist Therapeutics is owned by 111.60% institutional investors, 1.03% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 15.16% of PTGX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.95% of its assets in Protagonist Therapeutics shares.

PTGX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockProtagonist Therapeutics111.60%1.03%-12.63%
SectorHealthcare Stocks 488.17%11.08%-399.26%
IndustryBiotech Stocks 306.59%11.10%-217.69%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de9.63M15.16%$532.27M
Farallon capital management6.17M9.72%$341.13M
Blackrock5.76M9.39%$199.52M
Rtw investments, lp5.76M9.06%$318.15M
Vanguard group4.22M6.83%$162.89M
Deep track capital, lp3.25M5.11%$179.40M
Bvf inc/il3.21M5.06%$177.47M
Johnson & johnson2.45M3.86%$136.40M
State street2.08M3.40%$72.15M
Price t rowe associates inc /md/1.39M2.25%$53.76M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Johnson & johnson2.45M40.83%$136.40M
Lynx1 capital management lp733.01K12.69%$35.45M
Adar1 capital management948.07K8.04%$52.40M
Aquilo capital management81.69K7.08%$3.95M
Bvf inc/il3.21M6.34%$177.47M
Deep track capital, lp3.25M5.75%$179.40M
Checkpoint capital175.18K4.65%$8.47M
Rtw investments, lp5.76M4.53%$318.15M
Artia global partners lp333.85K4.09%$16.15M
Affinity asset advisors440.00K3.32%$24.32M

Top Buyers

HolderShares% AssetsChange
Wellington management group llp940.08K0.01%910.00K
Adage capital partners gp1.09M0.10%748.76K
Lynx1 capital management lp733.01K12.69%733.01K
Bvf inc/il3.21M6.34%636.03K
Holocene advisors, lp530.33K0.07%530.33K

Top Sellers

HolderShares% AssetsChange
Pacer advisors---1.88M
Morgan stanley345.29K0.00%-1.53M
State street2.08M0.00%-1.19M
Fairmount funds management---931.89K
Colony group---435.10K

New Positions

HolderShares% AssetsChangeValue
Lynx1 capital management lp733.01K12.69%733.01K$35.45M
Holocene advisors, lp530.33K0.07%530.33K$29.31M
Eagle asset management357.63K0.07%357.63K$12.59M
Nan fung trinity (hk)135.05K0.89%135.05K$7.46M
Millennium management134.27K0.00%134.27K$6.49M

Sold Out

HolderChange
Tfc financial management-1.00
Ifp advisors-5.00
Mendota financial group-6.00
Federated hermes-7.00
Nelson, van denburg & campbell wealth management group-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025279-3.79%70,876,6488.54%1111.04%1673.73%78-13.33%
Mar 31, 202519-92.31%15,761,655-75.08%250.24%12-91.18%5-93.33%
Dec 31, 2024147-40.49%31,832,545-48.43%510.52%84-45.81%42-35.38%
Sep 30, 202424627.46%61,406,0774.02%991.07%15469.23%65-7.14%
Jun 30, 20241932.66%59,030,802-1.50%960.99%91-17.27%7027.27%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.70M5.95%540.00
Vanguard Total Stock Mkt Idx Inv1.94M3.12%-41.38K
Vanguard US Total Market Shares ETF1.87M3.05%129.62K
Pacer US Small Cap Cash Cows 100 ETF1.61M2.63%-11.71K
iShares Russell 2000 ETF1.37M2.20%-26.04K
SPDR® S&P Biotech ETF977.79K1.58%24.09K
UBS: US Equity Small Cap Growth744.87K1.25%-
T. Rowe Price Health Sciences685.46K1.11%-86.97K
Vanguard Institutional Extnd Mkt Idx Tr665.61K1.07%-291.62K
Fidelity Small Cap Index584.22K0.94%-18.06K

Recent Insider Transactions


DateNameRoleActivityValue
Aug 27, 2025Waddill William D.-Sell$237.00K
Jul 25, 2025PATEL DINESH V PH D President and CEOSell$570.53K
Jul 21, 2025PATEL DINESH V PH D President and CEOSell$705.44K
Jul 23, 2025PATEL DINESH V PH D President and CEOSell$959.92K
Jul 22, 2025PATEL DINESH V PH D President and CEOSell$1.21M

Insider Transactions Trends


DateBuySell
2025 Q3-5
2025 Q2-3
2025 Q1-8
2024 Q4-8
2024 Q3-4

PTGX Ownership FAQ


Who Owns Protagonist Therapeutics?

Protagonist Therapeutics shareholders are primarily institutional investors at 111.60%, followed by 1.03% insiders and -12.63% retail investors. The average institutional ownership in Protagonist Therapeutics's industry, Biotech Stocks , is 306.59%, which Protagonist Therapeutics falls below.

Who owns the most shares of Protagonist Therapeutics?

Protagonist Therapeutics’s largest shareholders are Blackrock funding, inc. /de (9.63M shares, 15.16%), Farallon capital management (6.17M shares, 9.72%), and Blackrock (5.76M shares, 9.39%). Together, they hold 34.27% of Protagonist Therapeutics’s total shares outstanding.

Does Blackrock own Protagonist Therapeutics?

Yes, BlackRock owns 9.39% of Protagonist Therapeutics, totaling 5.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 199.52M$. In the last quarter, BlackRock increased its holdings by 188.63K shares, a 3.39% change.

Who is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested?

Johnson & johnson is Protagonist Therapeutics’s biggest shareholder by percentage of total assets invested, with 40.83% of its assets in 2.45M Protagonist Therapeutics shares, valued at 136.4M$.

Who is the top mutual fund holder of Protagonist Therapeutics shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Protagonist Therapeutics shares, with 5.95% of its total shares outstanding invested in 3.7M Protagonist Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools